InvestSMART

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) - Announcements

- Current share price for NSB : $0.066

ASX company news and announcements for NeuroScientific Biopharmaceuticals Ltd (NSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All NeuroScientific Biopharmaceuticals Ltd (NSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than NeuroScientific Biopharmaceuticals Ltd (NSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for NeuroScientific Biopharmaceuticals Ltd (NSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 Corporate Governance Statement 30 Aug 2022 8:03AM $0.240 $0.066 fallen by 72.50%
$26 Appendix 4G 30 Aug 2022 8:02AM $0.240 $0.066 fallen by 72.50%
$26 NeuroScientific releases FY2022 Results 30 Aug 2022 8:02AM $0.240 $0.066 fallen by 72.50%
$26 2022 Annual Report and Appendix 4E 30 Aug 2022 8:02AM $0.240 $0.066 fallen by 72.50%
$26 R&D Tax Incentive Refund Received 17 Aug 2022 8:12AM $0.250 $0.066 fallen by 73.60%
$26 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2022 6:05PM $0.200 $0.066 fallen by 67%
$26 HREC Submission for Phase I Clinical Trial 12 Jul 2022 9:50AM $0.200 $0.066 fallen by 67%
$26 First Subject Recruited for Early-Phase Clinical Trial 30 Jun 2022 10:07AM $0.175 $0.066 fallen by 62.29%
$26 Notification of cessation of securities - NSB 27 Jun 2022 4:19PM $0.195 $0.066 fallen by 66.15%
$26 Company Presentation - Gold Coast Investment Showcase 22 Jun 2022 12:19PM $0.190 $0.066 fallen by 65.26%
$26 Clarification of Results in MS Animal Study 22 Jun 2022 8:22AM $0.165 $0.066 fallen by 60%
$26 Notification regarding unquoted securities - NSB 21 Jun 2022 1:52PM $0.170 $0.066 fallen by 61.18%
$26 Issue of Employee Options 21 Jun 2022 1:40PM $0.170 $0.066 fallen by 61.18%
$26 Positive results in MS animal study 15 Jun 2022 8:23AM $0.175 $0.066 fallen by 62.29%
$26 Ethics Approval Granted for Early-Phase Clinical Trial 7 Jun 2022 11:17AM $0.230 $0.066 fallen by 71.30%
$26 HREC Submission for early-phase Clinical Trial 11 May 2022 9:22AM $0.220 $0.066 fallen by 70%
$26 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2022 8:00AM $0.285 $0.066 fallen by 76.84%
$26 Positive safety result supports advance to clinical trials 13 Apr 2022 10:27AM $0.260 $0.066 fallen by 74.62%
$26 NSB Enhances Management Team 1 Apr 2022 10:23AM $0.285 $0.066 fallen by 76.84%
$26 Company Presentation 24 Mar 2022 5:42PM $0.285 $0.066 fallen by 76.84%
$26 NSB presenting at Broker Briefing Investor Webinar 23 Mar 2022 8:23AM $0.290 $0.066 fallen by 77.24%
$26 New data demonstrates EmtinB activity in autoimmune diseases 11 Mar 2022 8:19AM $0.285 $0.066 fallen by 76.84%
$26 NSB 1HY22 Key Activity Highlights 28 Feb 2022 10:03AM $0.280 $0.066 fallen by 76.43%
$26 Half Yearly Report and Accounts 28 Feb 2022 9:45AM $0.280 $0.066 fallen by 76.43%
$26 Successful completion of key studies in lead up to Phase I 8 Feb 2022 8:23AM $0.315 $0.066 fallen by 79.05%

151 - 175 of 407 results

Page 7 of 17

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.